Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in proportion of participants who did not need escape therapy (as… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
Intravenous magnesium sulfate + standard care may leads to lower proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (low certainty).
1 finding from 1 review
Proportion of people requiring ventilatory support (NIV or assisted ventilation) · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people requiring ventilatory support (NIV or assisted… compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review